INTRODUCTION
Angiogenesis and vasodilatation are two critical processes controlling the dramatic increases in placental blood flow, which is directly correlated with fetal growth, fetal survival, and neonatal birth weight [1, 2] . We and other researchers have obtained solid evidence showing that expressions of fibroblast growth factor-2 (FGF2) and vascular endothelial growth factor (VEGF) positively correlate to the placental vascular growth during pregnancy [1] [2] [3] [4] . Meanwhile, expression of endothelial nitric oxide (NO) synthase (NOS3) in placental tissues and cord blood NO concentrations increase in parallel with these angiogenic factors and placental blood flow [1] [2] [3] [4] . These data implicate that interplays between FGF2, VEGF, and NOSderived NO play an important role in the integral regulation of placental angiogenesis and vasodilatation [5] .
Apart from being a potent vasodilator, it is of note that NO is capable of directly promoting endothelial mitosis and migration (two essential steps of angiogenesis). With bovine coronary venular endothelial cells, Ziche et al. [6, 7] have previously reported that exogenous NO stimulates endothelial cellular DNA synthesis, proliferation, and migration in vitro. Exogenous NO also mediates in vivo angiogenic responses induced by a vasoactive agent substance P in a rabbit ''cornea pocket assay,'' in which angiogenesis could be completely inhibited by the NOS inhibitor L -N G -Nitroarginine methyl ester ( L -NAME) [7] . More recently, we observed a direct stimulatory role of NO in ovine fetoplacental endothelial (OFPAE) cell proliferation, in part, via activation of the mitogen-activated protein kinase 1 and 2/mitogen-activated protein kinase 3/1 (MAP2K1/2/MAPK3/1) cascade [8] .
Previous studies have shown that VEGF-, but not FGF2-, induced in vivo angiogenesis is mediated via the NO/cGMP pathway [9, 10] . A clear role of NO as a downstream signal in VEGF-induced angiogenesis is further supported by many in vivo observations, including those made in rabbit ischemia models [11] , NOS3 knockout mice [12] , and NOS3 overexpressed rats [13] . Although the role of NO in the FGF2-induced angiogenesis is less conclusive, Babaei et al. [14] showed that NO functions as a crucial signal in the angiogenic response to FGF2 by promoting endothelial cell differentiation into capillary-like tube structures while terminating the proliferative actions with both human umbilical vein (HUVE) and calf pulmonary artery endothelial cell lines. Recently, we have also shown that FGF2-stimulated cell proliferation is associated with increased NOS3 protein expression in OFPAE cells [15, 16] . These studies, therefore, suggest that NO can function as an intermediate signal, which differentially regulates different steps of the angiogenic process upon FGF2 and VEGF stimulation.
Both FGF2 and VEGF initiate the cellular responses when they bind to and subsequently activate their respective specific tyrosine kinase receptors, thereby triggering multiple downstream protein kinase pathways [9, 10, 14, [17] [18] [19] . Among these pathways, the MAP2K1/2 (also termed MEK1/2)/ MAPK3/1) (also termed as ERK1/2) and phosphatidylinositol 3 kinase (PI3K)/v-akt murine thymoma viral oncogene homolog 1 (AKT1) pathways are the best studied. Of interest, activation of these two kinase pathways by FGF2 and VEGF may lead to the same angiogenic response in one endothelial cell type or distinct angiogenic responses in the other endothelial cell type. For example, the NO/cGMP/MAPK3/1 pathway mediates VEGF-, but not FGF2-, induced cell proliferation in bovine coronary venular endothelial cells [9, 10] , whereas in HUVE cells, such a cell response could be mediated by the PI3K/NOS3/NO pathway [20] . In other cases, parallel activation of MAP2K1/2 and PI3K pathways is required for maximal FGF2-induced endothelial cell proliferation [18] . Moreover, the signaling control mechanisms of FGF2-and VEGF-induced angiogenesis could be further complicated by cross-talks between these two pathways because activated MAPK3/1 or upstream kinases of MAP2K1/2 are capable of activating the PI3K/AKT1 pathway [21, 22] , which, in turn, either inhibits [21] [22] [23] [24] or potentiates [25] the MAP2K1/2/MAPK3/1 pathway. Thus, FGF2-and VEGF-activated MAPK3/1 and AKT1 pathways may act in a parallel, synergistic, or antagonistic manner [26] .
Relatively little is known about the postreceptor signaling pathways governing FGF2-and VEGF-induced placental angiogenesis. Therefore, in the present study, we investigated the role of intracellular signaling pathways in FGF2-and VEGF-stimulated endothelial proliferation with the OFPAE cell line as a model. We evaluated in OFPAE cells 1) whether and how endogenous NO mediated cell proliferation; 2) whether the MAP2K1/2/MAPK3/1 and PI3K/AKT1 mediated FGF2-and VEGF-stimulated cell proliferation; and 3) whether NO mediated FGF2-and VEGF-induced activation of MAPK3/1 and AKT1.
MATERIALS AND METHODS

Cell Preparation
The OFPAE cell line was established in our laboratory [4] . All OFPAE cells used in this study were at passages 8- 
Measurement of Total NO Levels in Culture Media
The concentration of total NO (nitrite and nitrate, NOx) in culture media was determined by chemiluminescence with an NO Analyzer (Sievers Instruments, Boulder, CO) as described previously [27, 28] . After 16 h of serum starvation, cells were treated without or with 10 ng/ml of FGF2 or VEGF for 0, 6, 12, 24, or 36 h. Samples (100 ll/treatment) of media collected were injected into the analyzer. The chemiluminescence signal generated by NOx was recorded and processed. Total NOx was calculated by a standard curve generated with sodium nitrate (100 nM-100 lM; Sigma-Aldrich, St. Louis, MO) as the standard. All data were normalized by the protein content of corresponding wells and corrected by subtracting those from the corresponding medium control (cells were treated with media only).
Cell Proliferation Assay
Cell proliferation assays were carried out as described [8, 15, 28] . We have previously shown that FGF2 and VEGF at 10 ng/ml significantly stimulated OFPAE cell proliferation [15] . Cells were cultured in 96-well plates (2000 cells/well) in Dulbecco modified Eagle medium (DMEM) containing 10% fetal bovine serum and 1% penicillin-streptomycin (all from Gibco-BRL, Gaithersburg, MD) and cultured for 48 h. To examine the effects of endogenous NO on FGF2-and VEGF-stimulated cell proliferation, L-argininefree DMEM, which was specially formulated by Gibco-BRL, was used. Cells were serum deprived in this DMEM supplemented with 25 lM L-arginine (Gibco-BRL) and 0.1% BSA for 16 h. Cells were treated with bovine FGF2 (R & D Systems, Minneapolis, MN), or human recombinant VEGF 165 (PeproTech, Inc., Rocky Hill, NJ) at 10 ng/ml in the absence or presence of N G -monomethyl-L-arginine (L-NMMA) (25, 250 , 2500, and 5000 lM; CalBiochem, San Diego, CA), N G -monomethyl-D-arginine (D-NMMA, 2500 and 5000 lM; CalBiochem), or phenyl-4,4,5,5 tetramethylimidazoline-1-oxyl 3-oxide (PTIO) (Sigma-Aldrich; a potent extracellular NO scavenger [8] ; 6.25-50 lM). In preliminary studies, we observed that a minimum of 12.5 lM Larginine was required for FGF2-induced cell growth and for maintaining cell viability and normal morphology. To determine the roles of the MAP2K1/2/ MAPK3/1 and PI3K/AKT1 pathways, cells were treated in a similar fashion, except that during serum starvation and growth factor treatments, cells were cultured in regular DMEM, which contained approximately 400 lM L-arginine and was supplemented with 0.1% BSA. Cells were treated with FGF2 or VEGF 165 in the absence or presence of PD98059 (a selective MAP2K1/2 inhibitor, 1-h pretreatment; CalBiochem) and/or LY 294002 (PI3K inhibitor, 1-h pretreatment; CalBiochem). After an additional 48 h of growth factor treatments, the numbers of cells were determined by the crystal violet assay [8, 15, 28] . Wells containing known cell numbers (0, 5000, 10 000, 20 000, or 40 000 cells/well; 6-well/cell density) were treated in a similar fashion to establish standard curves.
Western Immumoblot Analysis for MAPK3/1 and AKT1
Immunoblot analysis was performed as described previously [8, 15, 16, 28] . After 16 h of serum deprivation, OFPAE cells were treated for 0-60 min with FGF2 or VEGF (10 ng/ml). In the previous study, we demonstrated that both FGF2 and VEGF rapidly activate MAPK3/1, beginning after 5 min of treatment, reaching maximum levels at 10 min, and decreasing after 20 min [15] . In the present study, time dependence of AKT1 phosphorylation was first determined. Additional cells were treated for 10 min with FGF2 or VEGF in the absence or presence of PD98059 (20 lM, 1-h pretreatment) or LY294002 (5 lM, 1-h pretreatment). Controls included cells cultured with medium and the inhibitors alone. To examine the effects of NO on FGF2-and VEGFstimulated cell proliferation, additional cells were treated in a similar fashion, except that during serum starvation and growth factor treatment, cells were cultured in the DMEM containing only 25 lM L-arginine in the absence or presence of L-NMMA (5000 lM) or D-NMMA (5000 lM). Cells were washed with ice-cold PBS, harvested, and lysed by sonication in buffer (4 mM sodium pyrophosphate; 50 mM Hepes, pH 7.5; 100 mM NaCl; 10 mM EDTA; 10 mM sodium fluoride; 2 mM sodium orthovanadate [Na 3 VO 4 ]; 1 mM PMSF; 1% Triton X-100; 5 lg/ml of leupeptin; and 5 lg/ml of aprotinin). The lysates were centrifuged, and protein concentrations of the supernatants were determined. Proteins (2.5 lg/lane for MAPK3/1, 10-15 lg/lane for AKT1) were separated on 12% SDS-PAGE gels, electroblotted onto Immobilon-P membranes (Millipore, Bedford, MA), immunoblotted with either rabbit phospho-specific (1:2000) or total MAPK3/1 (1:2000) or phospho-specific (AKT1 473; 1:1000) or total AKT1 (1:2000) antibody. All of these four antibodies were purchased from Cell Signaling Technology (Beverly, MA). The MAPK3/1 and AKT1 on the membranes were visualized by a chemiluminescence system (Amersham Life Science Inc., Arlington Heights, IL) and quantified by scanning densitometry (model GS 670; Bio-Rad, Hercules, CA).
Statistical Procedures
All data were analyzed by a one-way analysis of variance (SigmaStat; Jandel Scientific, San Rafael, CA). When an F test was significant, data were compared with their respective control by Bonferroni multiple comparisons or the Student t-test. Data are reported as the mean 6 SEM.
RESULTS
Both FGF2 and VEGF Increased Total NOx Levels
Both FGF2 and VEGF time-dependently increased NOx levels in the medium (Fig. 1) . For VEGF, the stimulatory effect on total NOx levels was detectable (P , 0.05) after 6 h of 144 treatment, continued to increase by 12 h, and remained elevated up to 36 h. For FGF2, the stimulatory effect appeared after 6-and 12-h treatments and reached statistical significance (P , 0.05) after a 24-h treatment. The stimulatory effect of VEGF on NOx levels was more robust (;2-to 4-fold from 6 to 36 h) than that of FGF2.
L-NMMA, but not PTIO, Inhibited FGF2-and VEGFStimulated Cell Proliferation L-NMMA at high (2.5 and 5 mM), but not low (25 and 250 lM), concentrations significantly (P , 0.05) inhibited FGF2-and VEGF-induced cell proliferation (Fig. 2) . These two inhibitory doses of L-NMMA were 100-and 200-fold above L-arginine concentrations (25 lM), which is a typical excess amount required for competitive inhibition. D-NMMA at 2.5 and 5 mM did not affect the FGF2-and VEGF-induced cell proliferation. Neither L-NMMA alone at all doses studied nor D-NMMA alone at 2.5 and 5 mM significantly changed cell numbers after 2 days of culture (Fig. 2) , indicating that L-NMMA and D-NMMA do not reduce cell viability. PTIO, a potent extracellular NO scavenger, from 6.25 to 50 lM did not have a significant effect on the FGF2-and VEGF-stimulated cell proliferation (Fig. 2, C and D) .We have recently reported that PTIO at 50 lM exhausted NO released from 1 lM of sodium nitroprusside SNP (a potent NO donor) and greatly reduced NO levels released from 10 lM of SNP on OFPAE cells [8] , at which concentrations SNP releases much higher levels of NO than OFPAE cells (J. Zheng et al., unpublished results).
PD98059 and LY294002 Inhibited FGF2-and VEGFStimulated Cell Proliferation
Both FGF2-and VEGF-stimulated OFPAE cell proliferation was dose-dependently inhibited (P , 0.05) by PD98059 and LY294002 (Fig. 3 ). PD98059 decreased (P , 0.05) FGF2-stimulated cell proliferation at 10 and 20 lM but not at 2.5 and 5 lM (Fig. 3A) . VEGF-stimulated cell proliferation was inhibited (P , 0.05) by PD98059 at 2.5-10 lM and abolished (P , 0.05) at 20 lM (Fig. 3B) . LY294002 significantly reduced (P , 0.05) FGF2-stimulated cell proliferation at 2.5-5.0 lM, whereas it completely blocked (P , 0.05) VEGFstimulated cell proliferation at 2.5 lM (Fig. 3, C and D) . LY294002 at 0.625 and 1.25 lM did not alter either FGF2-or VEGF-stimulated cell proliferation (Fig. 3, C and D) . In the 
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absence of FGF2 and VEGF, PD98059 at 40 lM, but not below 20 lM, and LY294002 at 10 lM, but not below 5 lM, significantly (P , 0.05) decreased cell numbers (Fig. 3) . These data suggest that toxic effects of these inhibitors on OFPAE cells occurred only at these relatively high concentrations.
Because either PD98059 or LY294002 at concentrations studied only partially reduced FGF2-stimulated cell proliferation (Fig. 3, A and C) , we determined whether treating cells with both PD98059 (20 lM) and LY294002 (5 lM) simultaneously could completely abrogate FGF2-stimulated cell proliferation. We observed that treatment with a combination of PD98059 and LY294002 did completely inhibit (P , 0.05) FGF2-stimulated cell proliferation but that it also greatly decreased (P , 0.05) cell numbers in the absence of FGF2 (Fig. 4) , indicating that the combination of PD98059 and LY294002 at their respective nontoxic doses are toxic for OFPAE cells.
Effects of PD98059, LY294002, and L-NMMA on Phosphorylation of MAPK3/1 and AKT1
We have previously shown that in OFPAE cells, both FGF2 and VEGF at 10 ng/ml time-dependently and rapidly ( 5 min) activated MAPK3/1 without altering total MAPK3/1 levels [15] . In the present study, we demonstrated that FGF2 and VEGF also rapidly ( 10 min) increased phosphorylation levels of AKT1, without changing total AKT1 levels (Fig. 5) . Proteins were separated on SDS-PAGE gels and analyzed by immunoblotting with antibodies against phospho-specific (pAKT1) or total AKT1 (tAKT1). Data averaged from three independent experiments are expressed as means 6 SEM fold of the control. Means with asterisks and number symbols differ significantly (P , 0.05) from the control for FGF2 and VEGF treatments, respectively.
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Interestingly, unlike FGF2-induced MAPK3/1 phosphorylation, which lasts only ;10 min after activation, FGF2-induced AKT1 phosphorylation was sustained much longer (for up to 60 min after the treatment).
To examine if there are cross-talks between the MAP2K1/2/ MAPK3/1 and PI3K/AKT1 signaling pathways, cells were treated with FGF2 or VEGF in the absence or presence of PD98059 (20 lM) or LY294002 (5 lM). The doses of these inhibitors, generally considered highly selective for the corresponding kinase, were chosen on the basis of their inhibitory effects on cell proliferation as shown in Figure 1 . PD98059 and LY294002 greatly decreased (P , 0.05) FGF2-and VEGF-induced phosphorylation of MAPK3/1 (Fig. 6) and AKT1 (Fig. 7) , respectively. LY294002 reduced (P , 0.05) VEGF-, but not FGF2-, induced phosphorylation of MAPK3/1 (Fig. 6 ). PD98059 did not affect FGF2-and VEGF-induced phosphorylation of AKT1 (Fig. 7) . To determine if endogenous NO plays a role in the FGF2-and VEGF-induced MAPK3/1 and AKT1 pathways, cells were treated with L-NMMA and then challenged with growth factors. We found that treatment of cells with L-NMMA failed to change FGF2-and VEGFinduced phosphorylation of MAPK3/1 (Fig. 8) and AKT1 (Fig. 9) .
DISCUSSION
To better understand the intracellular signaling mechanisms governing FGF2-and VEGF-induced placental angiogenesis, we examined whether endogenous NO and protein kinase pathways (MAPK3/1 and AKT1) participate in mediating FGF2-and VEGF-stimulated cell proliferation with an ovine fetoplacental artery endothelial cell model. The involvement of endogenous NO in both FGF2-and VEGF-stimulated OFPAE cell proliferation is identified. We provide, for the first time, evidence that such involvement of NO is mediated primarily via an intracellular but not an autocrine and/or paracrine mechanism(s) because PTIO, an extracellular NO scavenger, does not alter the FGF2-and VEGF-stimulated cell proliferation. Our findings also demonstrate that activation of the MAP2K1/2/MAPK3/1 and PI3K/AKT1 pathways is critical for FGF2-stimulated cell proliferation, whereas activation of either pathway is sufficient for mediating the VEGF-induced maximal cell proliferation. Thus, our data indicate that these two kinase pathways differentially mediate the FGF2-and VEGF-stimulated OFPAE cell proliferation. Moreover, our data suggest that NO functions as a downstream signal of MAPK3/1 and AKT1 during the FGF2-and VEGF-stimulated OFPAE cell proliferation, as treatment with L-NMMA had no significant impact on the activation of MAPK3/1 and AKT1 induced by FGF2 and VEGF.
Placental NO production increases during normal sheep pregnancy [27, 29] and is associated with elevations in local expression of FGF2 and VEGF, vascular density, and blood flow to the placentas [30, 31] . Moreover, the increased NO production is highly correlated to protein expression of NOS3, but not NOS2 (also known as inducible NOS), in ovine placentas [27] , suggesting that NOS3 is the major NOS isoform responsible for the increased NO. These associations led us to hypothesize that there are close interactions between angiogenic factors and NO in the placentas. This premise is supported by our current data showing stimulatory effects of FGF2 and VEGF on NO production by OFPAE cells, which is consistent with reports showing such actions of FGF2 and VEGF on endothelial cells derived from other nonplacental tissues [11-14, 18, 32-40] . Intriguingly, even though FGF2, but not VEGF, increases NOS3 protein expression in OFPAE cells [15, 16] , VEGF is much more potent than FGF2 in stimulating NO production in OFPAE cells (Fig. 1) . These data suggest that FGF2 and VEGF stimulate NO production by increasing NOS3 protein expression (FGF2) or directly enhancing enzymatic activity of NOS3 (FGF2/VEGF) in OFPAE cells. However, it is apparent that different mechanisms are involved in FGF2 and VEGF regulation of NO production and NOS3 expression in OFPAE cells, which needs to be investigated. Together, our current data further support the critical role of FGF2 and VEGF in regulation of placental vasodilatation, in addition to their angiogenic activities [1] [2] [3] [4] .
NO has been reported to mediate VEGF-, but not FGF2-, induced cell proliferation and migration in bovine venular endothelial cells [9, 10] . Babaei et al. [14] , however, have demonstrated that NO plays different roles at different steps of the FGF2-induced angiogenesis. They showed that NO terminates FGF2-induced cell proliferation while promoting formation of capillary-like tube structures in both human umbilical core vein and calf pulmonary artery endothelial cells. In keeping with the role of NO as a critical downstream signal for FGF2-and VEGF-induced angiogenesis [9, 10, 14] , our current data, however, show that endogenous NO participates in both FGF2-and VEGF-stimulated OFPAE cell proliferation. Thus, NO plays a different role at different steps in the FGF2-and/or VEGF-stimulated angiogenesis (i.e., proliferation/migration vs. formation of capillary-like tube structures), which possibly depends on the origin (vascular bed) or developmental stage of the endothelial cells studied.
The VEGF can induce endothelial cell proliferation and migration via activation of the NO/cGMP/MAPK3/1 [9, 10] or PI3K/NOS3/NO [20, 38] pathway, suggesting that NO can act as either an upstream or downstream signal in angiogenic factor-induced activation of protein kinases in endothelial cells. Our current data that the NOS inhibitor, L-NMMA, fails to affect the activation of MAPK3/1 or AKT1 induced by FGF2 
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and VEGF support the notion that NO lies downstream of MAPK3/1 and AKT1 activation [15, 16, 32, 33] . Alternatively, it is plausible, but highly unlikely, that NO functions in parallel of MAPK3/1 and AKT1 activation. Moreover, it is also possible that, in turn, FGF2-and VEGF-increased NO induces activation of these protein kinases, if the increased NO can reach relatively high levels comparable to those released from exogenous NO donors [8-10, 15, 16, 41] .
Both FGF2-and VEGF-induced cellular responses are mediated via activation of multiple protein kinases, including MAPK3/1 and AKT1 [14, [17] [18] [19] . Our present study clearly demonstrates that the MAP2/K1/2/MAPK3/1 and PI3K/AKT1 pathways are critical in mediating both FGF2-and VEGFstimulated OFPAE cell proliferation. Of note is that VEGFstimulated OFPAE cell proliferation is much more sensitive to PD98059 and LY294002 than FGF2-stimulated cell proliferation. For example, the minimal concentration of PD98059 effectively inhibiting VEGF-stimulated cell proliferation is 4-fold ( 2.5 vs. 10 lM) lower than that inhibiting the FGF2-induced action. Moreover, PD98059 at 20 lM, a maximal concentration without affecting the cell number after 2 days of treatment in the absence of FGF2 and VEGF, inhibits FGF2-stimulated cell proliferation only by approximately 38% while reducing FGF2-induced phosphorylation of MAPK3/1 by approximately 85% and 68%. Similarly, LY294002 at 5 lM decreases FGF2-stimulated cell proliferation by approximately 45% while abolishing FGF2-induced AKT1 phosphorylation. These observations indicate that FGF2-stimulated cell proliferation is mediated partially via activation of the MAP2/K1/2/ MAPK3/1 and PI3K/AKT1 pathways. However, it remains to be elucidated whether synergic activation of both pathways is required for the complete FGF2 induction of OFPAE cell proliferation because of cytotoxic effects of the combined PD98059 and LY294002 on OFPAE cells, as shown in Figure  4 . In contrast to FGF2-induced actions, PD98059 at 20 lM and LY294002 at 5 lM block both VEGF-stimulated cell proliferation and phosphorylation of MAPK3/1 and AKT1, indicating that a complete VEGF-induced cell proliferation could be mediated via activation of either of these two pathways. Thus, in OFPAE cells, the MAP3K1/MAPK3/1 and PI3K/AKT1 pathways differentially mediate FGF2-and VEGF-stimulated cell proliferation.
The integration of the intracellular signaling pathways through complex cross-talks is poorly understood, particularly in the endothelium. Parallel activation of both MAPK3/1 and PI3K by FGF2 has been reported in bovine choriocapillary endothelial cells [18] . AKT1, however, upon its activation by MAPK3/1 or the upstream kinases of MAP2K1/2, could either inhibit [21] [22] [23] [24] or synergistically enhance [25] the MAP2K1/2/ MAPK3/1 pathway in certain nonendothelial cells. In this study, we found that PD98059 failed to alter either FGF2-or VEGF-induced phosphorylation levels of AKT1 in OFPAE cells. These data suggest that the MAP2K1/2/MAPK3/1 pathway does not mediate the PI3K/AKT1 pathway in OFPAE cells. However, we cannot exclude the possibility that the upstream kinases of MAP2K1/2 participate in such cross-talk. In contrast, LY294002 reduced VEGF-, but not FGF2-, induced phosphorylation levels of MAPK3/1. The inhibitory effect was modest but reached statistical significance. These data suggest that the activated PI3K/AKT1 pathway promotes VEGF-induced MAPK3/1 activation in OFPAE cells, but the underlying mechanism awaits further investigation.
In conclusion, we have demonstrated in the present study that increased intracellular NO and activation of multiple protein kinases are critical for both FGF2-and VEGFstimulated fetoplacental endothelial cell proliferation. Our data suggest that interactions among FGF2, VEGF, and NO play an important role in the integral regulation of placental angiogenesis and vasodilatation. Thus, these data advance our understanding of the complex signaling mechanism controlling placental angiogenesis and vasodilatation. Our data may also provide clues for developing useful means for modulating placental vasculature functions and blood flows by altering the signaling pathways activated by the angiogenic factors.
